News
NICE says NHS should fund Novartis' £1.79m SMA gene therapy
The NHS should pay for Novartis’ £1.79 million one-off gene therapy for Spinal Muscular Atrophy (SMA) NICE has said, the most expensive treatment ever approved for funding.
